Mir, A.; Vartak, R.V.; Patel, K.; Yellon, S.M.; Reznik, S.E. Vaginal Nanoformulations for the Management of Preterm Birth. Pharmaceutics2022, 14, 2019.
Mir, A.; Vartak, R.V.; Patel, K.; Yellon, S.M.; Reznik, S.E. Vaginal Nanoformulations for the Management of Preterm Birth. Pharmaceutics 2022, 14, 2019.
Mir, A.; Vartak, R.V.; Patel, K.; Yellon, S.M.; Reznik, S.E. Vaginal Nanoformulations for the Management of Preterm Birth. Pharmaceutics2022, 14, 2019.
Mir, A.; Vartak, R.V.; Patel, K.; Yellon, S.M.; Reznik, S.E. Vaginal Nanoformulations for the Management of Preterm Birth. Pharmaceutics 2022, 14, 2019.
Abstract
Preterm birth is a leading cause of infant morbidity and mortality in the world. In 2020, 1 in 10 infants were born prematurely in the United States. Globally, the World Health Or-ganization estimates 15 million infants are born prematurely. The efficacy of current ther-apeutic interventions for preterm birth have been called into question due to limited repli-cable success. Recent advancements in the field of nanomedicine have made it possible to utilize the vaginal administration route to effectively and locally deliver drugs to the fe-male reproductive tract. Also, studies using murine models have provided important in-sights about the cervix as a gatekeeper for pregnancy and parturition. It seems plausible that the field of reproductive biology is on the cusp of a paradigm shift in the context of treating preterm birth. The present review focuses on the complexities associated with treating the condition and novel therapeutics that have produced promising results in pre-clinical studies.
Biology and Life Sciences, Biology and Biotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
